Bristol-Myers Squibb
RANK
82
The New York City–based pharmaceutical company delivered strong financial results in 2021, with total revenue growing 9% year over year to $46.4 billion. Bristol-Myers Squibb enjoyed strong sales for drugs like Revlimid and Opdivo, used in the treatment of certain cancers; and Eliquis, an anticoagulant. Its product-development pipeline also looks healthy: In 2021, the company obtained more than 20 regulatory approvals for new medicines.
Illustration by Moukkaa
Company Information
As of 2/1/2023
Country
U.S.
Headquarters
New York City
Industry
Pharmaceuticals
CEO
Giovanni Caforio
Website
Company Type
Public
Ticker
BMY
Revenues ($M)
$46,738
Profits ($M)
$6,677
Market Value ($M)
$157,655
Employees
32,200
Figures are for the latest twelve months ended Sept. 30, 2022. Market value as of Jan. 20, 2023. Sources: Bloomberg; S&P Global.
Key Financials (Last Fiscal Year)
$ millions
% change
Revenues ($M)
$46,385
9.1%
Profits ($M)
$6,994
-
Assets ($M)
$109,314
-
Total Stockholder Equity ($M)
$35,946
-
Profit Ratios
Profit as % of Revenues
15.1%
Profits as % of Assets
6.4%
Profits as % of Stockholder Equity
19.5%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)
312
EPS % Change (from 2020)
-
EPS % Change (5 year annual rate)
3.3%
EPS % Change (10 year annual rate)
3.7%
Total Return
Total Return to Investors (2021)
3.7%
Total Return to Investors (5 year, annualized)
4.4%
Total Return to Investors (10 year, annualized)
9.1%
Bristol-Myers Squibb Rank History
Historical Data
| Year | Revenues ($M) | Profits ($M) | Assets ($M) | Total Stockholder Equity ($M) |
|---|---|---|---|---|
| 2021 | $42,51862.6% | $-9,015-362.1% | $118,481 | $37,822 |
| 2020 | $26,14515.9% | $3,439-30.1% | $129,944 | $51,598 |
| 2019 | $22,5618.6% | $4,920388.6% | $34,986 | $14,031 |
| 2018 | $20,7766.9% | $1,007-77.4% | $33,551 | $11,741 |
| 2017 | $19,42717.3% | $4,457184.8% | $33,707 | $16,177 |
SHOW MORE
Lists ranking Bristol-Myers Squibb
Latest news for Bristol-Myers Squibb
- Newsletters
What a Bristol-Myers project to monitor off-label prescribing says about future uses of A.I.January 25, 2022, 4:18 PM UTC - Conferences
Leaders from Peloton, Chobani, and more on how brands earn their purposeOctober 13, 2021, 2:15 PM UTC - Health
Booster shots and a big jump in market value: 3 takeaways from Moderna’s Q2 earningsAugust 5, 2021, 9:32 PM UTC - Tech
British A.I. drug discovery startup Exscientia buys Austrian cancer cell screening companyJune 15, 2021, 8:00 AM UTC
- Most Powerful Women 2021 - Building Brands With Purpose;49:13Conferences, MPW Summit;
- Brainstorm Health 2022 - Leveling The Playing Field: Transforming Patient Equity And Access;58:07Conferences, Brainstorm Health;
- Brainstorm Health 2022 - Accelerating Scientific Breakthroughs - The Power of Next Gen Therapies;46:16Conferences, Brainstorm Health;
- Bristol Myers Squibb CEO details promising acquisitions, healthcare message to Biden administration;7:58Series, On Leading;
